Merck has entered into a partnership valued at up to $3.65 billion with a Boston-area biotechnology firm pioneering a new class of what are known as circular RNA therapies.
Under the collaboration agreement, Merck (NYSE: MRK) will make an upfront payment of $150 million to Orna Therapeutics of Cambridge, Massachusetts. Orna is eligible for up to an additional $3.5 billion in additional payments tied to achieving a variety of development, regulatory, and sales milestones. Merck will also invest $100…
